Abstract Background and Aims Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by the production of organ-specific autoantibodies to components cell nucleus, immune complex lesions connective tissue, development irreversible damage internal organs. Chronic relapsing course SLE, resistance steroid immunosuppressive therapy, toxic effects drugs determine need searc...

Background Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels serologic markers without activity. The outcome and treatment strategy after SACQ achievement remains unclear. After achieving the goal, maintaining low-dose glucocorticoids has always been both blessing curse [1,2] . Whether discontinuation desirabl...

Background: the role of interferon pathways in pathogenesis systemic lupus erythematosus (SLE) has been proven over past years. Existing data suggest that score (IFN I score) may serve as a useful marker disease activity and patient clinical characteristics. Objectives: to compare characteristics pediatric SLE patients with high normal IFN score. Methods: 40 (33 girls, 7 boys) under 18 years ol...

Background Intercurrent infections are presumed potential triggers of systemic lupus erythematosus (SLE) disease flares. (1) However, most the evidence is obtained from a limited number observational studies, and results these studies conflicting. (2,3) Objectives To determine whether intercurrent risk factor for flares in SLE. Methods Demographic clinical characteristics 203 SLE patients Amste...

Background: Even in the hands of experienced clinicians, clinical phenotyping and predicting treatment responses Systemic Lupus Erythematosus (SLE) patients remains challenging. Therefore, identification biomarkers that can help physicians to divide into subgroups based upon aberrantly activated pathways is relevant might guide future strategies. Extensive blood transcriptional profiling has id...

To the Editor: Small case series have suggested that lenalidomide may be a promising therapeutic option for severe cutaneous lupus erythematosus (CLE).1Cortés-Hernández J. Ávila G. Vilardell-Tarrés M. Ordi-Ros Efficacy and safety of refractory erythematosus.Arthritis Res Ther. 2012; 14: R265Crossref PubMed Scopus (51) Google Scholar, 2Fennira F. Chasset Soubrier Cordel N. Petit A. Francès C. Le...

Background Systemic lupus erythematosus (SLE) is a heterogeneous disease with interaction of innate and adaptive immunity in pathogenesis clinical activity. Monocyte its subset role SLE activity not well defined. Complement levels dsDNA are used for monitoring but less than perfect there need newer prognostic markers management. Objectives To assess the utility monocyte subsets,circulating immu...

Background: Treat-to-target in systemic lupus erythematosus (SLE) has been proposed for 7 years and several recommendations were developed [1]. In these recommendations, prevention of flares should be a realistic target. Meanwhile, ‘remission’ or ‘low disease activity’ was recommended as the treatment target minimizing glucocorticoids (GC) dose withdrawal if possible suggested maintenance treat...

Background Fatigue in SLE has a multifactorial origin and disease activity seems to contribute only minimally its genesis. Therefore, non-pharmacological therapeutic strategies should also be considered the management of fatigue. There is some evidence on effectiveness aerobic exercise programs improving fatigue, without negative impact manifestations. Objectives aim this study was analyze fati...